Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CVID
MCID: CMM004
MIFTS: 71

Common Variable Immunodeficiency (CVID)

Categories: Blood diseases, Gastrointestinal diseases, Immune diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Common Variable Immunodeficiency

About this section

MalaCards integrated aliases for Common Variable Immunodeficiency:

Name: Common Variable Immunodeficiency 38 12 76 53 25 59 37 29 55 6 44 15 73
Cvid 12 53 25 59
Idiopathic Immunoglobulin Deficiency 53 59
Common Variable Immune Deficiency 53 25
Acquired Hypogammaglobulinemia 12 73
Primary Hypogammaglobulinemia 53 59
Primary Antibody Deficiency 53 59
Common Variable Hypogamma-Globulinemia 53
Immunoglobulin Deficiency, Late-Onset 53
Common Variable Hypogammaglobulinemia 25
Common Variable Agammaglobulinemia 12
Immunodeficiency, Common Variable 25
Hypogamma-Globulinemia, Acquired 53
Sporadic Hypogammaglobulinemia 12
Acquired Agammaglobulinemia 12

Characteristics:

Orphanet epidemiological data:

59
common variable immunodeficiency
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable; Prevalence: 1-9/100000; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases Gastrointestinal diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare immunological diseases


Sources

Summaries for Common Variable Immunodeficiency

About this section
Genetics Home Reference : 25 Common variable immune deficiency (CVID) is a disorder that impairs the immune system. People with CVID are highly susceptible to infection from foreign invaders such as bacteria, or more rarely, viruses and often develop recurrent infections, particularly in the lungs, sinuses, and ears. Pneumonia is common in people with CVID. Over time, recurrent infections can lead to chronic lung disease. Affected individuals may also experience infection or inflammation of the gastrointestinal tract, which can cause diarrhea and weight loss. Abnormal accumulation of immune cells causes enlarged lymph nodes (lymphadenopathy) or an enlarged spleen (splenomegaly) in some people with CVID. Immune cells can accumulate in other organs, forming small lumps called granulomas.

MalaCards based summary : Common Variable Immunodeficiency, also known as cvid, is related to immunodeficiency, common variable, 1 and immunodeficiency, common variable, 2. An important gene associated with Common Variable Immunodeficiency is TNFRSF13B (TNF Receptor Superfamily Member 13B), and among its related pathways/superpathways are Primary immunodeficiency and Innate Immune System. The drugs Rifaximin and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and t cells, and related phenotypes are chronic otitis media and splenomegaly

Disease Ontology : 12 A hypogammaglobulinemia that is results in insufficient production of antibodies needed to respond to exposure of pathogens and is characterized by low Ig levels with phenotypically normal B cells that can proliferate but do not develop into Ig-producing cells. Patients with common variable immunodeficiency have marked reduction in serum levels of both immunoglobulin G (IgG) and immunoglobulin A (IgA); about half of these patients also have reduced immunoglobulin M (IgM).

NIH Rare Diseases : 53 Common variable immunodeficiency (CVID) is a group of disorders in which the immune system cannot make antibodies against agents that cause infection (such as bacteria). CVID is characterized by low levels of most or all of the immunoglobulin (Ig) classes. This causes affected people to get frequent infections, particularly in the sinuses, lungs, and digestive tract. Symptoms most commonly begin in early adulthood but have been found in children as young as age two. While in most cases the cause of CVID is unknown, it has been associated with changes (mutations) in at least 10 genes. About 10% of cases are due to mutations in the TNFRSF13B gene. Treatment for CVID includes Ig replacement therapy, which stops the cycle of recurrent infections.

Wikipedia : 76 Common variable immunodeficiency (CVID) is an immune disorder characterized by recurrent infections and... more...

Sources

Related Diseases for Common Variable Immunodeficiency

About this section

Diseases related to Common Variable Immunodeficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 335)
# Related Disease Score Top Affiliating Genes
1 immunodeficiency, common variable, 1 33.7 ICOS NFKB2
2 immunodeficiency, common variable, 2 33.2 CD19 CR2 ICOS TNFRSF13B TNFRSF13C
3 agammaglobulinemia 32.4 BTK CD19 CR2
4 primary agammaglobulinemia 31.9 TNFRSF13B TNFRSF13C
5 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.2 BTK CD40LG IL2 SH2D1A
6 immunoglobulin a deficiency 1 30.6 BTK CD40LG TNFRSF13B
7 agammaglobulinemia, x-linked 30.5 BTK CD40LG IL2 SH2D1A
8 systemic lupus erythematosus 30.4 CD19 CD40LG CR2 IL2 IL21 TNFRSF13B
9 autoimmune disease 30.3 CD40LG IL2 IL21 TNFRSF13B TNFRSF13C TNFSF13
10 viral infectious disease 30.3 CD40LG CD81 IL2
11 b-cell lymphomas 30.3 BTK MS4A1 NFKB2 TNFRSF13C TNFSF13B
12 lymphoproliferative syndrome 30.2 CD27 IL2 PRKCD SH2D1A
13 pfeiffer syndrome 30.1 CD40LG CR2 SH2D1A
14 autoimmune lymphoproliferative syndrome 30.1 IL2 LRBA PRKCD
15 hemophagocytic lymphohistiocytosis 30.0 CD27 CR2 SH2D1A
16 lymphoma, non-hodgkin, familial 30.0 CD19 CD27 CR2 IL2 MS4A1 SH2D1A
17 burkitt lymphoma 29.9 CD40LG CR2 MS4A1 SH2D1A TNFSF13B
18 leukemia, chronic lymphocytic 29.8 CD19 CD27 CD40LG CR2 IL2 MS4A1
19 b cell deficiency 29.7 BTK CD19 CD27 CD40LG CR2 NFKB2
20 immunodeficiency, common variable, 14 12.6
21 immunodeficiency, common variable, 10 12.3
22 diarrhea, glucose-stimulated secretory, with common variable immunodeficiency 12.3
23 lrba deficiency 11.8
24 immunodeficiency, common variable, 3 11.5
25 immunodeficiency, common variable, 4 11.5
26 immunodeficiency, common variable, 5 11.5
27 immunodeficiency, common variable, 6 11.5
28 immunodeficiency, common variable, 7 11.5
29 immunodeficiency, common variable, 11 11.5
30 immunodeficiency-centromeric instability-facial anomalies syndrome 1 11.3
31 familial cold autoinflammatory syndrome 3 11.3
32 autoimmune lymphoproliferative syndrome, type iii 11.3
33 immunoglobulin a deficiency 2 11.3
34 immunoglobulin g deficiency 11.3
35 lymphoproliferative syndrome, x-linked, 2 11.1
36 bronchiectasis with or without elevated sweat chloride 1 10.9
37 bronchiectasis with or without elevated sweat chloride 2 10.9
38 bronchiectasis with or without elevated sweat chloride 3 10.9
39 immunodeficiency, common variable, 8, with autoimmunity 10.9
40 immunodeficiency, common variable, 12 10.9
41 immunodeficiency, common variable, 13 10.9
42 bap1 tumor predisposition syndrome 10.7
43 immunoglobulin alpha deficiency 10.5
44 lung disease 10.5
45 lymphoma 10.4
46 interstitial lung disease 10.4
47 pneumonia 10.3
48 cryptococcal meningitis 10.3 TNFRSF13B TNFRSF13C TNFSF13B
49 immunodeficiency with hyper-igm, type 4 10.3 CD40LG TNFSF13B
50 igg4-related disease 10.3 TNFSF13 TNFSF13B

Graphical network of the top 20 diseases related to Common Variable Immunodeficiency:



Diseases related to Common Variable Immunodeficiency
Sources

Symptoms & Phenotypes for Common Variable Immunodeficiency

About this section

Human phenotypes related to Common Variable Immunodeficiency:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 chronic otitis media 59 32 hallmark (90%) Very frequent (99-80%) HP:0000389
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
3 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
4 brachycephaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0000248
5 emphysema 59 32 occasional (7.5%) Occasional (29-5%) HP:0002097
6 immunodeficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0002721
7 hemolytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001878
8 failure to thrive in infancy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001531
9 decreased antibody level in blood 59 32 hallmark (90%) Very frequent (99-80%) HP:0004313
10 lymphopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001888
11 anal atresia 59 32 frequent (33%) Frequent (79-30%) HP:0002023
12 purpura 59 32 frequent (33%) Frequent (79-30%) HP:0000979
13 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
14 lymphoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002665
15 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
16 bronchiectasis 59 32 frequent (33%) Frequent (79-30%) HP:0002110
17 pneumonia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002090
18 gastrointestinal stroma tumor 59 32 occasional (7.5%) Occasional (29-5%) HP:0100723
19 restrictive ventilatory defect 59 32 occasional (7.5%) Occasional (29-5%) HP:0002091
20 autoimmune thrombocytopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001973
21 recurrent bronchitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002837
22 posterior pharyngeal cleft 59 32 occasional (7.5%) Occasional (29-5%) HP:0006783
23 recurrent respiratory infections 59 Very frequent (99-80%)
24 elevated hepatic transaminases 59 Frequent (79-30%)
25 otitis media 59 Very frequent (99-80%)
26 abnormality of the liver 59 Frequent (79-30%)
27 elevated hepatic transaminase 32 frequent (33%) HP:0002910

GenomeRNAi Phenotypes related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.36 PRKCD
2 Decreased viability GR00221-A-1 10.36 BTK PRKCD
3 Decreased viability GR00221-A-2 10.36 BTK PRKCD
4 Decreased viability GR00221-A-3 10.36 BTK
5 Decreased viability GR00221-A-4 10.36 BTK
6 Decreased viability GR00240-S-1 10.36 CD40LG
7 Decreased viability GR00301-A 10.36 BTK
8 Decreased viability GR00381-A-1 10.36 CD19 IL21 TNFRSF13B
9 Decreased viability GR00402-S-2 10.36 BTK CD19 CD27 CD40LG CD81 CR2
10 no effect GR00402-S-1 9.96 BTK CD19 CD27 CD40LG CD81 CR2
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CD40LG IL2 NFKB1 NFKB2 TNFSF12
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BTK CD27 CD40LG IL2 NFKB1 NFKB2

MGI Mouse Phenotypes related to Common Variable Immunodeficiency:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.16 BTK CD19 CD27 CD40LG CD81 CR2
2 digestive/alimentary MP:0005381 9.8 BTK CD19 ICOS IL2 NFKB1 NFKB2
3 homeostasis/metabolism MP:0005376 9.8 BTK CD19 CD40LG CD81 CR2 ICOS
4 immune system MP:0005387 9.62 BTK CD19 CD27 CD40LG CD81 CR2
Sources

Drugs & Therapeutics for Common Variable Immunodeficiency

About this section

Drugs for Common Variable Immunodeficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
2 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
3 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antibodies Phase 4,Phase 3,Not Applicable
5 Immunoglobulins Phase 4,Phase 3,Not Applicable
6 Nucleic Acid Synthesis Inhibitors Phase 4,Not Applicable
7 Anti-Bacterial Agents Phase 4
8 rifamycin SV Phase 4
9 Gastrointestinal Agents Phase 4,Not Applicable
10 Rifamycins Phase 4
11 Immunoglobulin G Phase 4,Phase 3,Not Applicable
12 gamma-Globulins Phase 4,Phase 3,Not Applicable
13 Immunoglobulins, Intravenous Phase 4,Phase 3,Not Applicable
14 Rho(D) Immune Globulin Phase 4,Phase 3,Not Applicable
15 Complement System Proteins Phase 4,Not Applicable
16 Complement C1 Inactivator Proteins Phase 4
17 Complement C1 Inhibitor Protein Phase 4
18 Complement C1s Phase 4
19 Immunosuppressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
20 Complement Inactivating Agents Phase 4
21 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable
22
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
23
Ustekinumab Approved, Investigational Phase 1, Phase 2 815610-63-0
24
Busulfan Approved, Investigational Phase 2,Phase 1,Not Applicable 55-98-1 2478
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
26
Cyclophosphamide Approved, Investigational Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
27
Pentostatin Approved, Investigational Phase 2 53910-25-1 439693 40926
28
Mycophenolic acid Approved Phase 2 24280-93-1 446541
29
Prednisone Approved, Vet_approved Phase 2,Not Applicable 53-03-2 5865
30
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
31
Mesna Approved, Investigational Phase 2,Not Applicable 3375-50-6 598
32
Fludarabine Approved Phase 1, Phase 2,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
33
Thiotepa Approved, Investigational Phase 1, Phase 2,Phase 2 52-24-4 5453
34
Melphalan Approved Phase 2,Not Applicable 148-82-3 4053 460612
35
alemtuzumab Approved, Investigational Phase 2,Not Applicable 216503-57-0
36 interferons Phase 2
37 Interferon-alpha Phase 2
38 Antiviral Agents Phase 2,Not Applicable
39 Interleukin-12 Phase 1, Phase 2
40 Dermatologic Agents Phase 1, Phase 2,Not Applicable
41 Alkylating Agents Phase 1, Phase 2,Phase 2,Not Applicable
42 Antineoplastic Agents, Alkylating Phase 1, Phase 2,Phase 2,Not Applicable
43 Thymoglobulin Phase 1, Phase 2
44 Antilymphocyte Serum Phase 1, Phase 2,Not Applicable
45 Antimetabolites Phase 1, Phase 2,Phase 2,Not Applicable
46 Antimetabolites, Antineoplastic Phase 1, Phase 2,Phase 2,Not Applicable
47 Antirheumatic Agents Phase 2,Not Applicable
48 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
49 Vaccines Phase 2,Not Applicable
50
Xylometazoline Approved, Investigational Phase 1 526-36-3 5709

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 The Rifaximin Study in CVID Completed NCT01946906 Phase 4 Rifaximin
2 Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Completed NCT00520494 Phase 4 Vivaglobin
3 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
4 A Study to Evaluate the Benefit of RUCONEST® in Subjects With CVID Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
5 A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Completed NCT02247141 Phase 3
6 Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Completed NCT00322556 Phase 3 Immunoglobulins Intravenous (Human)
7 Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Completed NCT00168025 Phase 3 Immunoglobulins Intravenous (Human)
8 Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) Completed NCT00168012 Phase 3 Immunoglobulins Intravenous (Human)
9 Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy Completed NCT00542997 Phase 3
10 Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases Completed NCT01884311 Phase 3
11 Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Completed NCT01963143 Phase 3
12 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
13 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
14 A Clinical Study of Intravenous Immunoglobulin Completed NCT00468273 Phase 3 Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
15 Study of Efficacy of CDZ173 in Patients With APDS/PASLI Recruiting NCT02435173 Phase 2, Phase 3 CDZ173
16 Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial Unknown status NCT02661477 Phase 2 pegylated interferon alfa 2
17 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency Recruiting NCT02199496 Phase 1, Phase 2
18 Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies Recruiting NCT02579967 Phase 2 Immunosuppression Only Conditioning;Reduced Intensity Conditioning;Myeloablative Conditioning;GVHD Prophylaxis
19 Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Recruiting NCT03663933 Phase 2 Immunosuppression Only Conditioning (IOC);Reduced Intensity Conditioning (RIC);GVHD Prophylaxis
20 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
21 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
22 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
23 "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency Terminated NCT01489618 Phase 2
24 Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) Withdrawn NCT02789397 Phase 2 Rituximab (RTX) and Azathioprine (AZA);Placebo Administration
25 STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency Completed NCT00263237 Phase 1 STA-5326
26 B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency Completed NCT00024934 Phase 1 B-Lymphocyte Stimulator (BLyS)
27 Lymphocyte Immunophenotyping in Common Variable Immunodeficiency Unknown status NCT01196702
28 Improving the Diagnosis of Common Variable Immune Deficiency Unknown status NCT02680652
29 Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms Completed NCT00015431
30 Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency Completed NCT00004695 Not Applicable PEG-interleukin-2
31 Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin Completed NCT00661401 Not Applicable
32 Human IgGs and Endothelial Function in Vivo in Humans Completed NCT03534479 Not Applicable Polyclonal IgG
33 Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease Completed NCT02542228
34 The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease Completed NCT03211689 Not Applicable
35 GLILD Diagnosed in Children and Young Adults With Common Variable Immunodeficiency Recruiting NCT03648567
36 Improving the Diagnosis of Common Variable Immune Deficiency Recruiting NCT03335605
37 Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes Recruiting NCT00001244
38 Natural History of Bronchiectasis Recruiting NCT00943514
39 Severe PID With Lymphoproliferation and Neutropenia Recruiting NCT03427593 Not Applicable
40 Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders Recruiting NCT00895271
41 ENCAPSID Study : ENCApsulated Bacterial Infection and Primary, Secondary ImmunoDeficiency Recruiting NCT03721146
42 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies Recruiting NCT01652092 Not Applicable Alemtuzumab 0.3 mg;Cyclophosphamide;Busulfan;Fludarabine phosphate 40 mg;Melphalan;Alemtuzumab 0.2 mg;Busulfan;Fludarabine phosphate 30 mg;MESNA
43 Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI) Recruiting NCT01883921
44 Investigation of Immune Disorders and Deficiencies Active, not recruiting NCT01981785
45 Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide Enrolling by invitation NCT03188419
46 Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older Terminated NCT02960399 Not Applicable
47 Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States Terminated NCT00266513
48 Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies Terminated NCT00006054 Not Applicable anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;etoposide;methotrexate;methylprednisolone;prednisone

Search NIH Clinical Center for Common Variable Immunodeficiency

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Common Variable Immunodeficiency cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Common Variable Immunodeficiency:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Embryonic/Adult Cultured Cells Related to Common Variable Immunodeficiency:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905

Cochrane evidence based reviews: common variable immunodeficiency

Sources

Genetic Tests for Common Variable Immunodeficiency

About this section

Genetic tests related to Common Variable Immunodeficiency:

# Genetic test Affiliating Genes
1 Common Variable Immunodeficiency 29
Sources

Anatomical Context for Common Variable Immunodeficiency

About this section

MalaCards organs/tissues related to Common Variable Immunodeficiency:

41
B Cells, Lung, T Cells, Spleen, Lymph Node, Liver, Bone
Sources

Publications for Common Variable Immunodeficiency

About this section

Articles related to Common Variable Immunodeficiency:

(show top 50) (show all 1170)
# Title Authors Year
1
Common variable immunodeficiency presenting in a man with recurrent pneumonia caused by <i>Staphylococcus lugdunensis</i>. ( 29559491 )
2018
2
Evaluation of Clinical and Immunological Characteristics of Children with Common Variable Immunodeficiency. ( 29849668 )
2018
3
Keeping it in the family: the case for considering late-onset combined immunodeficiency a subset of common variable immunodeficiency disorders. ( 29806948 )
2018
4
Phenotypic characterization of patients with rheumatologic manifestations of common variable immunodeficiency. ( 29599028 )
2018
5
The circulating T helper subsets and regulatory T cells in patients with common variable immunodeficiency with no known monogenic disease. ( 29345621 )
2018
6
Common variable immunodeficiency associated with stiff-person syndrome. ( 29407421 )
2018
7
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. ( 29156507 )
2018
8
Chronic meningoencephalitis caused by Echo virusA 6 in aA patient with common variable immunodeficiency : Successful treatment with pleconaril. ( 29116409 )
2018
9
Psoriasiform dermatitis associated with common variable immunodeficiency 10 due to an Arg853* mutation in the NFKB2 gene. ( 29952021 )
2018
10
Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature. ( 29138951 )
2018
11
Intravenous immunoglobulin (IVIG) efficiency in women with common variable immunodeficiency (CVID) decreases significantly during pregnancy. ( 29614902 )
2018
12
Reversible Suppression of Lymphoproliferation and Thrombocytopenia with Rapamycin in a Patient with Common Variable Immunodeficiency. ( 29350338 )
2018
13
Cutaneous granulomas in a patient with common variable immunodeficiency disease. ( 29389055 )
2018
14
The Profile of Toll-like Receptor 2 (TLR2), TLR4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (CVID) Patients. ( 29757592 )
2018
15
Acute Gastrointestinal Bleeding Due to Cytomegalovirus Colitis in a Patient with Common Variable Immunodeficiency. ( 29850647 )
2018
16
Predictive markers for humoral influenza vaccine response in patients with common variable immunodeficiency. ( 29678747 )
2018
17
Allergic disease in patients with common variable immunodeficiency at a tertiary care referral center. ( 29273136 )
2018
18
Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. ( 29867916 )
2018
19
First case report of acquired generalized lipodystrophy associated with common variable immunodeficiency. ( 29846625 )
2018
20
Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency. ( 29574865 )
2018
21
Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID). ( 29453744 )
2018
22
Common Variable Immunodeficiency and Gastric Malignancies. ( 29393912 )
2018
23
Improvement of common variable immunodeficiency using embryonic stem cell therapy in a patient with lyme disease: a clinical case report. ( 29881587 )
2018
24
Autoimmune hepatitis as a complication of common variable immunodeficiency. ( 29368942 )
2018
25
HLA-A29 negative Birdshot-like chorioretinopathy associated with common variable immunodeficiency. ( 29780906 )
2018
26
Renal Evaluation in Common Variable Immunodeficiency. ( 29736405 )
2018
27
Familial inheritance and screening of first-degree relatives in common variable immunodeficiency and immunoglobulin A deficiency patients. ( 29978731 )
2018
28
Gastrointestinal and hepatobiliary manifestations in patients with common variable immunodeficiency: In relation to three clinical cases. ( 29691086 )
2018
29
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy. ( 30191508 )
2018
30
Bronchial Asthma and Bronchial Hyperresponsiveness and Their Characteristics in Patients with Common Variable Immunodeficiency. ( 30458444 )
2018
31
Early B cell developmental impairment with progressive B cell deficiency in NFKB2 mutated CVID disease without autoimmunity. ( 30500415 )
2018
32
The TH1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency. ( 28554560 )
2018
33
Granulomatous-Lymphocytic Interstitial Lung Disease in a Patient With Common Variable Immunodeficiency. ( 28583689 )
2018
34
Common Variable Immunodeficiency and Liver Involvement. ( 28785926 )
2018
35
Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing. ( 29030829 )
2018
36
Modulation of the Interleukin-21 Pathway with Interleukin-4 Distinguishes Common Variable Immunodeficiency Patients with More Non-infectious Clinical Complications. ( 29103189 )
2018
37
Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. ( 29477724 )
2018
38
Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. ( 29935219 )
2018
39
Gluten-free diet: a possible treatment for chronic diarrhoea in common variable immunodeficiency. ( 29991548 )
2018
40
A Novel Hypothesis on Excessive Activation of Residual B Lymphocytes in Common Variable Immunodeficiency Concurrent with Aseptic, Erosive Polyarthritis. ( 30011399 )
2018
41
Prosthetically Driven Therapy for a Patient with Systemic Lupus Erythematosus and Common Variable Immunodeficiency: A Case Report. ( 30036142 )
2018
42
A 56-Year-Old-Man With Common Variable Immunodeficiency and Worsening Dyspnea. ( 30044751 )
2018
43
Lung nodules in a patient with common variable immunodeficiency. ( 30060883 )
2018
44
Comparison of the Percentage of Regulatory T cells and their p-STAT5 Expression in Allergic and Non-Allergic Common Variable Immunodeficiency Patients. ( 30064289 )
2018
45
Pulmonary Manifestations of Common Variable Immunodeficiency. ( 30067570 )
2018
46
Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia? ( 30072997 )
2018
47
TNFRSF13B/TACI Alterations in Turkish Patients with Common Variable Immunodeficiency and IgA Deficiency. ( 30090215 )
2018
48
The first Polish cohort of adult patients with common variable immunodeficiency from 4 specialized centers: do we provide standards of care? ( 30113020 )
2018
49
In vitro chromosomal radiosensitivity in patients with common variable immunodeficiency. ( 30135627 )
2018
50
Fatigue and the wear-off effect in adult patients with common variable immunodeficiency. ( 30168848 )
2018
Sources

Variations for Common Variable Immunodeficiency

About this section

ClinVar genetic disease variations for Common Variable Immunodeficiency:

6 (show all 22)
# Gene Variation Type Significance SNP ID Assembly Location
1 TNFSF12 NM_003809.2(TNFSF12): c.338-9A> G single nucleotide variant Benign rs114577645 GRCh38 Chromosome 17, 7550934: 7550934
2 TNFSF12 NM_003809.2(TNFSF12): c.338-9A> G single nucleotide variant Benign rs114577645 GRCh37 Chromosome 17, 7454251: 7454251
3 TNFSF12 NM_003809.2(TNFSF12): c.498+9delC deletion Likely benign GRCh38 Chromosome 17, 7556911: 7556911
4 TNFSF12 NM_003809.2(TNFSF12): c.498+9delC deletion Likely benign GRCh37 Chromosome 17, 7460228: 7460228
5 TNFSF12 NM_003809.2(TNFSF12): c.609C> T (p.Leu203=) single nucleotide variant Benign rs140608168 GRCh38 Chromosome 17, 7557209: 7557209
6 TNFSF12 NM_003809.2(TNFSF12): c.609C> T (p.Leu203=) single nucleotide variant Benign rs140608168 GRCh37 Chromosome 17, 7460526: 7460526
7 TNFSF12 NM_003809.2(TNFSF12): c.642G> T (p.Gly214=) single nucleotide variant Benign rs4968189 GRCh38 Chromosome 17, 7557242: 7557242
8 TNFSF12 NM_003809.2(TNFSF12): c.642G> T (p.Gly214=) single nucleotide variant Benign rs4968189 GRCh37 Chromosome 17, 7460559: 7460559
9 TNFSF12 NM_003809.2(TNFSF12): c.43G> A (p.Glu15Lys) single nucleotide variant Uncertain significance rs768061768 GRCh37 Chromosome 17, 7452513: 7452513
10 TNFSF12 NM_003809.2(TNFSF12): c.43G> A (p.Glu15Lys) single nucleotide variant Uncertain significance rs768061768 GRCh38 Chromosome 17, 7549196: 7549196
11 TNFSF12 NM_003809.2(TNFSF12): c.42G> A (p.Gly14=) single nucleotide variant Likely benign GRCh38 Chromosome 17, 7549195: 7549195
12 TNFSF12 NM_003809.2(TNFSF12): c.42G> A (p.Gly14=) single nucleotide variant Likely benign GRCh37 Chromosome 17, 7452512: 7452512
13 TNFSF12 NM_003809.2(TNFSF12): c.597G> A (p.Ala199=) single nucleotide variant Benign rs143039184 GRCh38 Chromosome 17, 7557197: 7557197
14 TNFSF12 NM_003809.2(TNFSF12): c.597G> A (p.Ala199=) single nucleotide variant Benign rs143039184 GRCh37 Chromosome 17, 7460514: 7460514
15 TNFSF12 NM_003809.2(TNFSF12): c.450C> T (p.Ile150=) single nucleotide variant Likely benign rs147597489 GRCh37 Chromosome 17, 7460171: 7460171
16 TNFSF12 NM_003809.2(TNFSF12): c.450C> T (p.Ile150=) single nucleotide variant Likely benign rs147597489 GRCh38 Chromosome 17, 7556854: 7556854
17 TNFSF12 NM_003809.2(TNFSF12): c.177G> C (p.Glu59Asp) single nucleotide variant Uncertain significance rs868687352 GRCh37 Chromosome 17, 7452808: 7452808
18 TNFSF12 NM_003809.2(TNFSF12): c.177G> C (p.Glu59Asp) single nucleotide variant Uncertain significance rs868687352 GRCh38 Chromosome 17, 7549491: 7549491
19 TNFSF12 NM_003809.2(TNFSF12): c.679C> T (p.Arg227Cys) single nucleotide variant Uncertain significance GRCh38 Chromosome 17, 7557279: 7557279
20 TNFSF12 NM_003809.2(TNFSF12): c.679C> T (p.Arg227Cys) single nucleotide variant Uncertain significance GRCh37 Chromosome 17, 7460596: 7460596
21 TNFSF12 NM_003809.2(TNFSF12): c.205_207dup (p.Ser69_Glu70insSer) duplication Uncertain significance GRCh38 Chromosome 17, 7549519: 7549521
22 TNFSF12 NM_003809.2(TNFSF12): c.205_207dup (p.Ser69_Glu70insSer) duplication Uncertain significance GRCh37 Chromosome 17, 7452836: 7452838
Sources

Expression for Common Variable Immunodeficiency

About this section
Search GEO for disease gene expression data for Common Variable Immunodeficiency.
Sources

Pathways for Common Variable Immunodeficiency

About this section

Pathways related to Common Variable Immunodeficiency according to KEGG:

37
# Name Kegg Source Accession
1 Primary immunodeficiency hsa05340

Pathways related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.01 BTK CD19 CD27 CD40LG CD81 ICOS
2
ERK Signaling 64
Show member pathways
 13.86 BTK CD27 CD40LG IL2 IL21 NFKB1
3
PEDF Induced Signaling 64
Show member pathways
 13.69 BTK CD27 CD40LG IL2 IL21 NFKB1
4
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.43 BTK CD19 CD40LG CD81 ICOS NFKB1
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.37 CD27 CD40LG IL2 NFKB1 NFKB2 PRKCD
6
Akt Signaling 64
Show member pathways
 13.36 BTK CD27 CD40LG IL2 IL21 NFKB1
7
PAK Pathway 64
Show member pathways
 13.21 BTK CD27 CD40LG IL2 IL21 NFKB1
8
IL-2 Pathway 64
Show member pathways
 13.19 BTK CD19 CD81 CR2 IL2 NFKB1
9
Development Angiotensin activation of ERK 22
Show member pathways
 12.92 BTK CD27 CD40LG NFKB1 PRKCD TNFRSF13B
10
Allograft rejection 1 37
Show member pathways
 12.84 CD40LG ICOS IL2 IL21 NFKB1 NFKB2
11
NF-KappaB Family Pathway 64
Show member pathways
 12.74 CD40LG IL2 NFKB1 NFKB2 PRKCD TNFRSF13C
12
4-1BB Pathway 64
Show member pathways
 12.66 CD27 CD40LG CR2 NFKB1 PRKCD
13
Immune response NFAT in immune response 22
Show member pathways
 12.65 BTK CD40LG ICOS IL2 NFKB1 NFKB2
14
Immune response Fc epsilon RI pathway 22
Show member pathways
 12.61 BTK CD19 CD81 CR2 NFKB1 NFKB2
15
TRAF Pathway 64
Show member pathways
 12.49 BTK CD27 CD40LG NFKB1 PRKCD TNFRSF13B
16
RANK Signaling in Osteoclasts 64
Show member pathways
 12.48 CR2 NFKB1 NFKB2 TNFRSF13B TNFRSF13C TNFSF13
17
T cell receptor signaling pathway 37
Show member pathways
 12.44 CD40LG ICOS IL2 NFKB1 PRKCD
18
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.43 BTK CD19 CD81 CR2 NFKB1 PRKCD
19
Apoptosis Pathway 72
Show member pathways
 12.41 IL2 NFKB1 NFKB2 PRKCD
20
ICos-ICosL Pathway in T-Helper Cell 64
Show member pathways
 12.41 CD40LG ICOS IL2 NFKB1 PRKCD
21
Human T-cell leukemia virus 1 infection 37
12.4 IL2 NFKB1 NFKB2 TNFRSF13C
22
Epstein-Barr virus infection 37
12.32 BTK CD19 CR2 NFKB1 NFKB2
23
Development A3 receptor signaling 22
Show member pathways
 12.3 BTK NFKB1 NFKB2 PRKCD
24
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.3 BTK CD19 NFKB1 PRKCD
25
C-type lectin receptor signaling pathway 37
Show member pathways
 12.24 BTK IL2 NFKB1 NFKB2 PRKCD
26
NF-kappaB Signaling 4
12.17 BTK CD19 CD40LG ICOS IL2 NFKB1
27
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
12.07 CD19 CD40LG CD81 SH2D1A
28
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.06 BTK IL2 PRKCD TNFRSF13C TNFSF13B
29
MAPK Pathway 72
Show member pathways
 11.98 IL2 NFKB1 NFKB2
30
Spinal Cord Injury 1
11.96 IL2 TNFSF13 TNFSF13B
31
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.95 CD19 IL2 MS4A1
32
NF-kappa B signaling pathway 37
11.95 BTK CD40LG NFKB1 NFKB2 TNFRSF13C TNFSF13B
33
IL12-mediated signaling events 1
Show member pathways
 11.93 IL2 NFKB1 NFKB2
34
Hematopoietic cell lineage 37
11.86 CD19 CR2 MS4A1
35
Corticotropin-releasing hormone signaling pathway 1
11.84 IL2 NFKB1 PRKCD
36
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.84 IL21 NFKB1 NFKB2
37
LT-BetaR Pathway 64
Show member pathways
 11.78 IL2 NFKB1 NFKB2
38
Dendritic Cells Developmental Lineage Pathway 65
11.72 CD19 IL2 MS4A1
39
NF-kB (NFkB) Pathway 67
11.71 BTK NFKB1 PRKCD
40
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.69 CD40LG IL2 NFKB1 NFKB2
41
T Cell Co-Signaling Pathway: Ligand-Receptor Interactions 65
11.6 CD27 CD40LG ICOS
42
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 22
Show member pathways
 11.56 CD40LG NFKB1 NFKB2 TNFRSF13B TNFSF12 TNFSF13
43
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.49 BTK NFKB1 NFKB2
44
Tacrolimus/Cyclosporine Pathway, Pharmacodynamics 61
11.46 IL2 NFKB1 NFKB2
45
Primary immunodeficiency 37
11.37 BTK CD19 CD40LG ICOS TNFRSF13B TNFRSF13C
46
TNFs bind their physiological receptors 66
11.34 CD27 TNFRSF13B TNFSF13 TNFSF13B
47
G-protein signaling_RhoB regulation pathway 22
11.25 BTK CD40LG IL2 IL21 TNFSF12 TNFSF13
48
Telomere Extension by Telomerase 64
Show member pathways
 11.18 IL2 NFKB1 NFKB2
49
G-protein signaling_Rap2B regulation pathway 22
11.05 BTK CD40LG IL2 IL21 NFKB1 TNFSF12
50
B Cell Development Pathways 65
10.95 CD19 CD27 CD40LG CR2 ICOS IL21
Sources

GO Terms for Common Variable Immunodeficiency

About this section

Cellular components related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 CD19 CD27 CD40LG CD81 ICOS MS4A1
2 extracellular region GO:0005576 9.85 CD27 CD40LG ICOS IL2 IL21 NFKB1
3 plasma membrane GO:0005886 9.8 BTK CD19 CD27 CD40LG CD81 CR2
4 external side of plasma membrane GO:0009897 9.1 CD19 CD27 CD40LG ICOS MS4A1 TNFRSF13C
5 membrane GO:0016020 10.24 BTK CD19 CD27 CD40LG CD81 CR2
6 integral component of membrane GO:0016021 10.13 CD19 CD27 CD40LG CD81 CR2 ICOS

Biological processes related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.95 CD40LG IL2 IL21 PRKCD TNFSF12 TNFSF13
2 cell surface receptor signaling pathway GO:0007166 9.91 CD19 CD27 CD81 TNFRSF13B
3 adaptive immune response GO:0002250 9.89 BTK IL2 SH2D1A TNFRSF13B TNFRSF13C
4 immune response GO:0006955 9.86 CD40LG CR2 ICOS IL2 IL21 TNFSF12
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 BTK CD40LG NFKB1 NFKB2
6 regulation of complement activation GO:0030449 9.81 CD19 CD81 CR2
7 negative regulation of inflammatory response GO:0050728 9.8 IL2 NFKB1 PRKCD
8 regulation of immune response GO:0050776 9.8 CD19 CD40LG CD81 SH2D1A TNFRSF13C TNFSF13B
9 T cell costimulation GO:0031295 9.73 CD40LG ICOS TNFRSF13C TNFSF13B
10 B cell proliferation GO:0042100 9.67 CD40LG CR2 MS4A1 PRKCD
11 B cell homeostasis GO:0001782 9.65 TNFRSF13B TNFRSF13C TNFSF13B
12 positive regulation of natural killer cell mediated cytotoxicity GO:0045954 9.64 IL21 SH2D1A
13 positive regulation of T cell differentiation GO:0045582 9.64 CD27 IL2
14 negative regulation of B cell proliferation GO:0030889 9.63 BTK TNFRSF13B
15 negative regulation of cytokine production GO:0001818 9.61 BTK NFKB1
16 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.6 IL21 TNFRSF13C
17 positive regulation of interleukin-17 production GO:0032740 9.59 IL2 IL21
18 cellular response to angiotensin GO:1904385 9.58 NFKB1 PRKCD
19 immunoglobulin mediated immune response GO:0016064 9.58 CD27 PRKCD
20 positive regulation of B cell differentiation GO:0045579 9.57 BTK CD27
21 positive regulation of tissue remodeling GO:0034105 9.56 IL2 IL21
22 positive regulation of T cell proliferation GO:0042102 9.55 CD40LG IL2 IL21 TNFRSF13C TNFSF13B
23 immunoglobulin secretion GO:0048305 9.54 CD40LG TNFSF13B
24 B cell costimulation GO:0031296 9.52 TNFRSF13C TNFSF13B
25 positive regulation of germinal center formation GO:0002636 9.51 TNFRSF13C TNFSF13B
26 positive regulation of B cell proliferation GO:0030890 9.35 CD81 IL2 IL21 TNFRSF13C TNFSF13B
27 tumor necrosis factor-mediated signaling pathway GO:0033209 9.17 CD27 CD40LG TNFRSF13B TNFRSF13C TNFSF12 TNFSF13
28 positive regulation of cell proliferation GO:0008284 10.02 CD81 IL2 IL21 TNFSF13 TNFSF13B
29 immune system process GO:0002376 10 BTK CR2 IL2 SH2D1A TNFRSF13B TNFRSF13C

Molecular functions related to Common Variable Immunodeficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex binding GO:0023026 9.26 CD81 MS4A1
2 tumor necrosis factor receptor binding GO:0005164 9.26 CD40LG TNFSF12 TNFSF13 TNFSF13B
3 interleukin-2 receptor binding GO:0005134 9.16 IL2 IL21
4 cytokine activity GO:0005125 9.1 CD40LG IL2 IL21 TNFSF12 TNFSF13 TNFSF13B
5 protein binding GO:0005515 10.22 BTK CD19 CD27 CD40LG CD81 CR2
Sources

Sources for Common Variable Immunodeficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....